🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

CCEL CCEL

Company Profile ↓
$3.64
-28.77% 1Y
P/E-12.13
52W High$5.31
52W Low$2.89
EPS (TTM)$-0.30

Company Overview

CCEL (CCEL) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Healthy Margins

Operating margin of 15.3% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Nov 2025 Revenue of $31.57M (-1.3% YoY); net profit $-2.43M.
  • Trailing 12 Months Year-on-year growth — revenue -1.3%, earnings -704.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.3%, profit CAGR -62.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.33%
1 Year:-1.31%

Compounded Profit Growth

5 Years:-62.55%
1 Year:-704.18%

Stock Price Performance

1 Year:-28.77%
6 Months:+6.74%
3 Months:+3.12%
1 Month:+1.96%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 31% of range
$2.89 $5.31
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)56.86 · Neutral
Price Performance
1M+1.96%
3M+3.12%
6M+6.74%
1Y-28.77%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Earnings shrank at -62.6% CAGR over 5 years.
  • Trading 31.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-12.13
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
1.33%
Profit 5Y
-62.55%
Revenue (YoY)
-1.31%
Earnings (YoY)
-704.18%

Profitability & Returns

ROCE
11.54%
ROE
13.06%
ROA
-3.94%
Profit Margin
-7.70%
Op Margin
15.34%
Gross Margin
76.63%
EPS (Latest Qtr)
$0.07
EPS (TTM)
$-0.30

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$60.71M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
42.03%
Chg in Prom Hold
-
FII / Inst Holding
13.44%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$31.57M
EBITDA
$1.10M
Free Cash Flow
$5.25M
Operating Cash Flow
$5.48M
Shares Outstanding
-
Gross Margin
76.63%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Feb 2014May 2014Aug 2014Feb 2015May 2015Aug 2015Feb 2016May 2016Aug 2016Feb 2017May 2017Aug 2017Feb 2018May 2018Aug 2018Feb 2019May 2019Aug 2019Feb 2020May 2020Aug 2020Feb 2021May 2021Aug 2021Feb 2022May 2022Aug 2022Feb 2023May 2023Aug 2023Feb 2024May 2024Aug 2024Nov 2024Feb 2025May 2025Aug 2025Nov 2025Feb 2026May 2026
Revenue 5.32M4.89M4.94M4.84M5.01M5.44M5.15M5.77M6.33M5.78M6.24M6.90M6.23M6.53M--------------------7.97M7.93M-7.84M7.68M7.78M
Cost of Revenue ----------------------------------1.98M1.86M-1.73M1.66M1.68M
Gross Profit ----------------------------------5.98M6.07M-6.11M6.03M6.10M
Operating Expenses ----------------------------------4.93M4.58M-5.72M5.26M4.90M
Operating Income 804.52K562.33K428.96K625.19K602.09K1.26M156.42K882.38K-1.06M1.12M1.19M1.45M987.14K1.15M920.12K853.66K496.56K1.99M1.25M1.75M2.48M1.24M2.00M1.60M1.47M1.19M954.31K1.68M1.03M1.16M821.22K1.39M1.39M-1.06M1.49M1.90M392.05K765.13K1.20M
EBITDA ----------------------------------1.37M1.47M--3.82M875.02K1.61M
Interest Expense ----------------------------------494.96K551.13K-481.95K462.71K441.92K
Pretax Income ----------------------------------533.72K575.10K--4.63M70.31K827.78K
Tax Provision ----------------------------------250.86K219.32K--814.54K23.20K273.19K
Net Income 397.11K215.77K236.57K286.17K210.03K7.83M-122.94K637.13K-2.64M486.92K496.94K652.02K-2.53M539.51K244.98K275.88K53.67K1.12M686.97K953.34K784.47K693.59K1.17M856.49K832.05K634.72K466.82K766.81K220.98K680.56K556.24K655.79K1.05M-282.86K355.79K749.41K-3.82M47.11K554.59K
Diluted EPS 0.040.020.020.030.020.80-0.010.07-0.350.070.060.08-0.360.070.030.030.010.130.080.120.100.080.140.100.100.070.060.090.030.080.070.080.13-0.030.040.09-0.010.07
R&D Expense 14.37K18.32K17.85K11.99K10.53K9.95K8.68K11.99K13.78K14.62K8.84K22613.41K29.28K22.23K5.88K4.96K2.44K5.72K9.82K1.25K6.19K3.24K10.00K147.22K80.90K80.27K78.83K304.68K344.13K502.89K241.09K193.93K-98.14K131.71K61.62K-65.76K99.78K

Profit & Loss (Annual)

Figures in USD.

Metric Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Revenue 17.76M17.92M17.97M18.99M20.13M21.09M23.13M25.38M29.22M31.82M31.15M-30.34M31.34M31.99M31.57M
Cost of Revenue ------------8.79M8.39M7.95M7.38M
Gross Profit ------------21.54M22.95M24.04M24.19M
Operating Expenses ------------17.08M19.46M20.25M19.35M
Operating Income 3.35M-276.74K-1.71M1.70M1.98M2.93M433.59K5.01M5.19M5.06M7.66M-4.46M3.49M3.79M4.84M
EBITDA ------------6.65M-10.42M5.69M1.10M
Interest Expense ------------1.52M1.24M1.86M2.07M
Pretax Income ------------3.32M-13.36M2.80M-2.34M
Tax Provision ------------547.54K-3.84M2.40M92.23K
Net Income 3.46M-2.10M-6.31M27.44K553.62K8.11M-1.32M2.32M-854.82K2.29M3.62M-2.77M-9.52M402.10K-2.43M
Diluted EPS 0.29-0.18-0.560.000.050.83-0.160.30-0.110.270.45-0.33-1.150.05-0.30
R&D Expense 132.99K184.05K109.64K36.17K64.37K45.78K53.10K41.16K91.84K30.14K23.85K49.87K384.79K1.17M1.24M376.26K

Balance Sheet (Annual)

Figures in USD.

Metric Nov 2009Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Total Assets -18.09M19.47M12.33M11.50M10.21M19.50M19.54M23.91M42.39M42.89M46.20M60.66M64.89M61.22M64.68M61.73M
Total Equity -4.69M-1.00M-2.46M-9.00M-9.27M-10.73M-4.96M-15.41M-12.50M-8.91M-6.95M-2.67M4.18M-1.52M-11.03M-13.22M-18.61M
Cash & Equivalents 6.85M8.37M6.31M2.68M3.93M3.28M4.15M3.50M6.28M6.04M6.54M10.36M8.26M1.70M406.07K560.96K319.03K
Long Term Debt -3.75M2.85M2.30M2.30M2.30M2.30M1.43M1.43M1.43M8.96M5.94M1.90M8.73M8.60M8.48M8.35M
Total Liabilities ------24.46M34.95M36.41M51.30M49.84M48.87M56.48M66.41M72.25M77.89M80.33M
Current Liabilities -8.26M10.56M10.66M9.81M9.13M10.42M13.11M13.94M15.43M15.43M16.41M21.07M19.48M20.86M21.60M19.79M

Cash Flows (Annual)

Figures in USD.

Metric Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Operating Cash Flow 2.34M819.12K360.90K821.98K---5.72M5.33M6.29M8.47M7.93M8.57M8.92M6.01M5.48M
Investing Cash Flow -819.62K-2.96M962.36K1.15M---93.03K-11.28M-662.29K357.49K-6.95M-15.28M-8.14M-4.88M-975.33K
Financing Cash Flow -80.94K-4.95M-723.67K----3.03M5.71M-5.13M-5.00M-3.07M147.86K-2.07M-979.12K-4.75M
Capital Expenditure -398.90K-505.71K-133.54K-349.78K-120.52K-108.48K-342.98K-98.33K-446.16K-662.29K-99.96K-1.83M-12.17M-6.84M-2.40M-230.47K
Free Cash Flow 1.94M313.41K227.36K472.20K---5.62M4.89M5.63M8.37M6.09M-3.60M2.08M3.61M5.25M
Share Buybacks --1.70M738.62K2.67M3.21M10.81M446.62K-992.24K-249.38K1.82M799.04K1.42M169.50K

Ratios (Annual)

Figures in %.

Metric Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Gross Margin % ------------71.0%73.2%75.2%76.6%
Operating Margin % 18.8%-1.5%-9.5%9.0%9.8%13.9%1.9%19.7%17.8%15.9%24.6%-14.7%11.1%11.8%15.3%
Net Margin % 19.5%-11.7%-35.1%0.1%2.8%38.4%-5.7%9.1%-2.9%7.2%11.6%-9.1%-30.4%1.3%-7.7%
ROE % -345.8%85.2%70.1%-0.3%-5.2%-163.3%8.6%-18.5%9.6%-32.9%-136.0%--181.8%86.3%-3.0%13.1%
ROCE % 34.0%-3.1%-102.7%100.7%183.0%32.3%6.7%50.2%19.2%18.4%25.7%-9.8%8.6%8.8%11.5%

Shareholding Pattern

Insiders
42.03%
Institutions
13.44%
Public Float
23.19%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CCEL

Google News Wed, 15 Jul 2026

$CCEL ($CCEL) Releases Q2 2026 Earnings - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNZTVMakF0NURLTXNIMzliOG5RN3o5X1dvM21HajNXNk1pYkZRNnAzcy1WTXdhUDRKNU02YWRSV2RZTmM5Uy1ITENmd0dMV20tQlREcVJRRDIzNnVaZlYtWHRwWHdsQXNkalVMRmZyZ2VsQWNkclFWOElMMXhxZmhJdzZId3ppVzQ?oc=5" …

Google News Fri, 08 May 2026

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American - Business Wire

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOVTVjcmVad2pJZjN0aWM5aC1WS0pXanBDemdldEs5eTNPYWlkT1ZaOHBVRndGaWlObldBVjVkdU1mX05Hclc4NGdwOUJWSDd6MUsxQXo3WmduN2lmdDdpVi03cUI1aGwwZ0hrNGxTOGktcTl4ZTJFOTVoYXg3d0J1YzJOWl9IbFVlR2hTR0…

Google News Fri, 31 Jul 2026

Cryo-Cell International Inc (CCEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE42X0tuWktUYXVRZlAzc3p5M3lRSUVHLWVhd1dCbHpwX1dvOFFZc1lwdFJNXzYwNnNidWhfcTlKN1ZxT1ZiV1pMT1MydEZqVnRzaFVSTlpkMzVoMG1POXJTcDh5dk0taGYzcjFVUWVrQV8?oc=5" target="_blank">Cryo-Cell Intern…

Google News hu, 30 Jul 2026

CCEL Q2 2026 Earnings: Positive Earnings Surprise as EPS Turns Profitable - Downward Estimate Revision - dars.gov.et

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPNzl6dzh1UEk5cEFhd2xXMDBsLXdyS1g3U3ZSRml2VXM1NERhYmRBcDVsSDQ3cFYwcHFGNnlwNVF2WDJpQm83WlBLYjZpN3dEclpBbWNSVVN0NXJmS1ZEZWZwaG5TWHBCZnlHODByYXZ0WVdaeFVDY1RKU3kzdmJmY2w2dU1uRzFpQTEtTU…

Google News Wed, 25 Mar 2026

Eric Shahinian Takes Activist Stake at Cryo-Cell International with 5.3% Stake - TradingView

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQQVZma0VuNENaT1VBb04tQzZFUkNEOXlPZHUxT2tLWXQ0Nk9DUmVrOF9BaW5rZzlJUXdGcnFrYUc0UkYtTjRfaXZtRjY0eEFJTE9JWV9rNm9LRVItcG1fT2NQYmlfbkRhUmdpbmd5RUVJVmd2bUxSMU54UUZvcjhYWlpzeGhldW5wZmFYVj…

Google News Fri, 31 Jul 2026

Cryo-Cell International Inc (CCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBIUThBRUozTlRQc2NJMU5qZ21YUWxPdktQcHBSOGNoOWZyNy1YZ2pDWGUyZXpLNUtRTmUwLXBnd1RLVmdvdExIeHJwNW5ndllNTHNKVXVpMmM4UFU5ZEg2dmdZak04TEY0SGdiS2xR?oc=5" target="_blank">Cryo-Cell Internati…

CCEL — Frequently Asked Questions

What is the current share price of CCEL?

As of 2026-08-05 17:25 PDT, CCEL trades at $3.64 on NASDAQ/NYSE. Its 52-week range is $2.89 to $5.31.

What is the P/E ratio of CCEL?

CCEL trades at a trailing price-to-earnings (P/E) ratio of -12.13.

What is the return on equity (ROE) of CCEL?

CCEL has a return on equity (ROE) of 13.06%. Its return on capital employed (ROCE) is 11.54%.

Is CCEL a good stock to buy?

This page provides a data-driven analysis of CCEL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space